Scientific Advisory Group for Origins of Novel Pathogens

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023
Biotechnology, General Health, Neurology, Health, Pharmaceutical, Aureus, Fidelity Investments, Marketing, Webcast, Investment, European Medicines Agency, Research, AMX0035, Fidelity, Regulation Fair Disclosure, ALS, EMA, CHMP, Scientific Advisory Group for Origins of Novel Pathogens, Neurodegenerative disease, European Directive on Traditional Herbal Medicinal Products, National Defense Authorization Act, U.S. FDA, Health Canada, Committee for Medicinal Products for Human Use, Medication, Committee, MAA, Physician, FDA, Marketing Authorisation Application, Regulation, Scientific Advisory Group, Risk management, Disclosure, Cryptocurrency, Pharmaceutical industry, Amylyx Pharmaceuticals, PHOENIX

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022.
  • Amylyx received U.S. FDA approval for RELYVRIO in September 2022 with the first commercial product being available in October 2022.
  • Financial Results for the Fourth Quarter and Year Ended December 31, 2022
    For the three months ended December 31, 2022, net product revenue was $21.9 million and cost of sales were $2.8 million.
  • Cash, cash equivalents, and short-term investments were $346.9 million at December 31, 2022, compared to $162.6 million at September 30, 2022.

COVID-19 Origins Investigation Must Continue, says AHF

Retrieved on: 
Thursday, February 16, 2023
Public Policy, Government, Advocacy Group Opinion, Health, COVID-19, Nature, Origin, AHF, Human, Scientific Advisory Group for Origins of Novel Pathogens, World Health Organization, AIDS Healthcare Foundation, Scientific Advisory Group, WHO, Global health, Pharmaceutical industry

Following reporting by Nature that the World Health Organization planned to abandon the second phase of its COVID-19 origins investigation and a quick rebuttal by WHO that it was still a go, AHF calls for the global health institution to continue its investigation and make its position unequivocally clear.

Key Points: 
  • Following reporting by Nature that the World Health Organization planned to abandon the second phase of its COVID-19 origins investigation and a quick rebuttal by WHO that it was still a go, AHF calls for the global health institution to continue its investigation and make its position unequivocally clear.
  • We have not, and we will not.”
    “Delaying or canceling the investigation into the origins of COVID-19 would be a catastrophic decision by the WHO and a huge detriment to global health security and future efforts to foster cooperation on pandemic prevention, preparedness, and response,” said AHF President Michael Weinstein.
  • “How COVID-19 started is still a big question, with many credible experts supporting the hypothesis that a laboratory accident is more likely than a zoonotic event.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .